Agency
Peacehealth
Peacehealth was paid $81.65M by Medicaid between Jan 2018 and Dec 2024, across 543 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 12% of everything it billed.
33Billing provider infoPEACEHEALTH
VANCOUVER, WA 98664
VANCOUVER, WA 98664
33aNPI1134178999assigned 05/09/2006
33bProvider typeCommunity Based Hospice Care Agency
28Total paid$81.65M
24GClaims2,504,976
24DCodes billed543
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Community Based Hospice Care Agency providers in Washington
Rank by total paid#1 of 19
Median peer was paid$265K
This provider vs. median308×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SEIRER, JEFFREY controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 394,535 | $14.06M | |
| 2019 | 370,191 | $12.71M | |
| 2020 | 324,618 | $10.01M | |
| 2021 | 367,003 | $12.07M | |
| 2022 | 359,620 | $12.29M | |
| 2023 | 373,458 | $11.00M | |
| 2024incomplete | 315,551 | $9.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 35,078 | 26,833 | $9.73M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.9% | 114,817 | 98,697 | $5.63M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.3% | 47,942 | 44,165 | $5.18M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.1% | 109,376 | 67,192 | $5.00M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.3% | 51,162 | 46,818 | $4.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 63,859 | 58,238 | $4.11M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.5% | 65,076 | 57,659 | $2.84M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 3.2% | 12,615 | 6,628 | $2.62M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 16,711 | 15,988 | $2.49M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.3% | 28,162 | 11,702 | $1.86M |
| H2012 | Behavioral health day treatment, per hour | 2.3% | 6,930 | 1,168 | $1.84M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 14,261 | 13,491 | $1.76M |
531 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 20,042 | $1.39M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 10,943 | $1.19M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 10,819 | $1.07M |
| 99203 | Doctor's office visit, new patient (routine) | 1.3% | 15,949 | $1.03M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 32,245 | $799K |
| Q5001 | Hospice or home health care provided in patient's home/residence | <1% | 4,211 | $766K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 32,452 | $713K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,849 | $706K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,016 | $658K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,797 | $644K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,384 | $636K |
| 80053 | Comprehensive metabolic panel | <1% | 112,624 | $578K |
| 87631 | <1% | 10,047 | $564K | |
| 59025 | Fetal non-stress test | <1% | 3,530 | $553K |
| 76830 | Ultrasound, transvaginal | <1% | 6,350 | $546K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 401 | $526K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 22,044 | $516K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 22,586 | $516K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,634 | $510K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,369 | $506K |
| 64483 | <1% | 1,848 | $475K | |
| 11045 | <1% | 3,260 | $459K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,164 | $447K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,521 | $396K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 376 | $384K |
| 70496 | <1% | 2,689 | $383K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 6,524 | $370K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,174 | $364K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,431 | $352K |
| 12001 | <1% | 1,754 | $350K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,539 | $339K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 15,201 | $327K |
| 96415 | <1% | 1,447 | $317K | |
| 76641 | <1% | 3,487 | $305K | |
| 10060 | <1% | 1,691 | $295K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 4,382 | $291K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,936 | $286K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,231 | $284K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 16,165 | $283K |
| 93971 | <1% | 3,588 | $279K | |
| G0378 | Hospital observation service, per hour | <1% | 12,853 | $277K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,060 | $265K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,134 | $262K |
| 76801 | <1% | 4,522 | $260K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,520 | $260K |
| 76536 | <1% | 2,992 | $258K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 564 | $256K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 982 | $247K |
| 36415 | Collection of venous blood by venipuncture | <1% | 68,088 | $244K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,571 | $240K |
| 96367 | <1% | 5,901 | $238K | |
| 97162 | <1% | 6,292 | $220K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,125 | $216K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 369 | $202K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 4,335 | $193K |
| 12011 | <1% | 908 | $191K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 103 | $184K |
| 76770 | <1% | 2,027 | $182K | |
| 84484 | <1% | 41,250 | $165K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,063 | $164K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 596 | $161K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,465 | $158K |
| 72141 | <1% | 1,192 | $154K | |
| 97597 | <1% | 10,059 | $153K | |
| 29125 | <1% | 846 | $153K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,342 | $148K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,917 | $145K |
| 71250 | <1% | 2,941 | $142K | |
| 93976 | <1% | 2,726 | $139K | |
| 64493 | <1% | 376 | $139K | |
| 76882 | <1% | 2,278 | $131K | |
| 20610 | <1% | 1,366 | $129K | |
| 12002 | <1% | 738 | $128K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,345 | $127K |
| 70491 | <1% | 1,022 | $122K | |
| 76870 | <1% | 1,283 | $119K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,753 | $119K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,763 | $118K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 19,378 | $118K |
| 97161 | <1% | 2,931 | $118K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 30,416 | $113K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 50,862 | $110K |
| 88307 | <1% | 2,648 | $107K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 190 | $107K |
| 30520 | <1% | 68 | $101K | |
| 70486 | <1% | 2,352 | $99K | |
| 47562 | <1% | 53 | $89K | |
| 70498 | <1% | 2,802 | $81K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,262 | $79K |
| 94660 | <1% | 365 | $78K | |
| 90837 | Psychotherapy session, about an hour | <1% | 889 | $78K |
| 83605 | <1% | 14,725 | $78K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 787 | $73K |
| 88342 | <1% | 6,011 | $72K | |
| 49083 | <1% | 186 | $70K | |
| 62323 | <1% | 342 | $69K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,824 | $67K |
| 15271 | <1% | 130 | $67K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 35,490 | $67K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,534 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,323 | $65K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 422 | $64K |
| G0515 | Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes | <1% | 237 | $63K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 435 | $63K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,470 | $60K |
| 93970 | <1% | 727 | $60K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 554 | $59K |
| 77066 | Tomosynthesis, mammo | <1% | 2,052 | $59K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 147 | $59K |
| 90715 | <1% | 3,764 | $55K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,567 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 125,181 | $53K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 976 | $52K |
| 71271 | <1% | 614 | $52K | |
| 81003 | <1% | 13,525 | $49K | |
| 81025 | <1% | 13,553 | $48K | |
| 11043 | <1% | 911 | $48K | |
| 93017 | <1% | 833 | $47K | |
| 62321 | <1% | 254 | $47K | |
| 73630 | <1% | 4,689 | $47K | |
| 97116 | <1% | 3,745 | $45K | |
| 97166 | <1% | 1,733 | $45K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,284 | $45K |
| H0031 | Mental health assessment, by non-physician | <1% | 781 | $44K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 435 | $44K |
| 97129 | <1% | 678 | $43K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 562 | $42K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 641 | $42K |
| 72100 | <1% | 2,510 | $39K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,335 | $39K |
| 73562 | <1% | 3,515 | $39K | |
| 73030 | <1% | 3,684 | $39K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,417 | $39K |
| 97113 | <1% | 789 | $38K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 5,308 | $38K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 691 | $37K |
| 87040 | <1% | 4,278 | $37K | |
| 90686 | <1% | 2,712 | $37K | |
| 77080 | <1% | 640 | $36K | |
| 73610 | <1% | 3,804 | $36K | |
| 83880 | <1% | 8,116 | $36K | |
| 29515 | <1% | 204 | $36K | |
| 76813 | <1% | 494 | $35K | |
| 62370 | <1% | 686 | $35K | |
| 36430 | <1% | 865 | $34K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,438 | $34K |
| 73130 | <1% | 3,558 | $33K | |
| 64635 | <1% | 69 | $33K | |
| 72131 | <1% | 967 | $31K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 38,959 | $31K |
| 77002 | <1% | 580 | $31K | |
| 97163 | <1% | 871 | $31K | |
| 99205 | Prolong outpt/office vis | <1% | 367 | $31K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,185 | $31K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 785 | $30K |
| 73110 | <1% | 2,647 | $30K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,330 | $29K |
| 99479 | Subsequent intensive care, per day, very low birth weight infant | <1% | 384 | $28K |
| 85379 | <1% | 5,390 | $28K | |
| 10061 | <1% | 124 | $27K | |
| 85610 | <1% | 24,391 | $27K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 162 | $26K |
| 80305 | <1% | 14,892 | $25K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 255 | $25K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 506 | $25K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,215 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,334 | $24K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 34,259 | $23K |
| 20553 | <1% | 271 | $23K | |
| 81001 | <1% | 31,740 | $23K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 582 | $22K |
| 95251 | <1% | 1,417 | $22K | |
| 74018 | <1% | 1,765 | $21K | |
| 98926 | <1% | 1,055 | $21K | |
| 62369 | <1% | 444 | $20K | |
| 73502 | <1% | 2,050 | $20K | |
| G0155 | Services of clinical social worker in home health or hospice settings, each 15 minutes | <1% | 401 | $20K |
| 93798 | <1% | 3,135 | $20K | |
| 88341 | <1% | 1,763 | $19K | |
| 77336 | <1% | 346 | $19K | |
| 42821 | <1% | 13 | $19K | |
| 72040 | <1% | 1,000 | $18K | |
| 73140 | <1% | 1,333 | $18K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,303 | $18K |
| 81002 | <1% | 5,763 | $17K | |
| 42826 | <1% | 13 | $17K | |
| 97804 | <1% | 790 | $16K | |
| 99460 | <1% | 192 | $16K | |
| 88304 | <1% | 3,825 | $15K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 650 | $15K |
| 83050 | <1% | 4,637 | $14K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 58 | $14K |
| 87081 | <1% | 3,861 | $14K | |
| 74174 | <1% | 254 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,330 | $13K |
| 73564 | <1% | 900 | $13K | |
| 84703 | <1% | 20,988 | $13K | |
| 93321 | <1% | 430 | $12K | |
| 73080 | <1% | 1,511 | $12K | |
| 70487 | <1% | 75 | $12K | |
| 97802 | <1% | 130 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 34,231 | $12K |
| 73221 | <1% | 78 | $11K | |
| 76942 | <1% | 180 | $11K | |
| 82728 | <1% | 2,972 | $10K | |
| 11046 | <1% | 22 | $10K | |
| 97130 | <1% | 640 | $10K | |
| 73590 | <1% | 1,468 | $10K | |
| 83690 | <1% | 31,707 | $9K | |
| 72158 | <1% | 76 | $9K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 618 | $9K |
| 83735 | <1% | 14,404 | $9K | |
| 82962 | <1% | 3,876 | $8K | |
| 77334 | <1% | 103 | $8K | |
| 77012 | <1% | 183 | $8K | |
| 36561 | <1% | 13 | $8K | |
| 86923 | <1% | 494 | $8K | |
| 84112 | <1% | 962 | $8K | |
| 83060 | <1% | 4,452 | $8K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 162 | $8K |
| 76642 | <1% | 90 | $7K | |
| 64400 | <1% | 29 | $7K | |
| 99469 | Subsequent inpatient neonatal critical care, per day, 28 days or younger | <1% | 31 | $7K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 73 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 23,340 | $7K |
| 93308 | <1% | 48 | $7K | |
| 82565 | <1% | 5,234 | $7K | |
| 97165 | <1% | 243 | $7K | |
| 15275 | <1% | 36 | $7K | |
| 73090 | <1% | 1,111 | $7K | |
| 72110 | <1% | 240 | $7K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 25 | $6K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 369 | $6K |
| 86850 | <1% | 6,153 | $6K | |
| 85027 | <1% | 8,332 | $6K | |
| 74183 | <1% | 28 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 19,392 | $6K |
| 86900 | <1% | 6,244 | $6K | |
| 72156 | <1% | 41 | $5K | |
| 93793 | <1% | 5,022 | $5K | |
| 80061 | Lipid panel | <1% | 1,609 | $5K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 216 | $5K |
| 90670 | <1% | 279 | $5K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 20 | $5K |
| 82607 | <1% | 1,267 | $5K | |
| 90688 | <1% | 331 | $5K | |
| 90677 | <1% | 94 | $5K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 102 | $5K |
| 97803 | <1% | 108 | $5K | |
| 74178 | <1% | 28 | $5K | |
| 73523 | <1% | 193 | $4K | |
| 93325 | <1% | 437 | $4K | |
| 90656 | <1% | 354 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 261 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 25,995 | $4K |
| 85060 | <1% | 375 | $4K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 67 | $4K |
| 73700 | <1% | 65 | $4K | |
| 84702 | <1% | 4,631 | $4K | |
| S9436 | Childbirth preparation/lamaze classes, non-physician provider, per session | <1% | 65 | $4K |
| 76376 | <1% | 3,901 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,412 | $4K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 2,660 | $4K |
| 29105 | <1% | 16 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 18,582 | $4K |
| 83550 | <1% | 2,272 | $4K | |
| 83540 | <1% | 2,296 | $3K | |
| D0120 | Dental checkup, returning patient | <1% | 441 | $3K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 32 | $3K |
| 96376 | <1% | 15,022 | $3K | |
| 88173 | <1% | 548 | $3K | |
| 72072 | <1% | 307 | $3K | |
| 87430 | <1% | 2,780 | $3K | |
| 99442 | <1% | 177 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,618 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,135 | $3K |
| 86901 | <1% | 7,610 | $3K | |
| 74230 | <1% | 71 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12,425 | $3K |
| 84439 | <1% | 2,817 | $3K | |
| 86140 | <1% | 3,802 | $3K | |
| 77001 | <1% | 64 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 282 | $3K |
| 99188 | <1% | 187 | $3K | |
| 74220 | <1% | 102 | $3K | |
| 82330 | <1% | 6,771 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 917 | $2K |
| 99252 | <1% | 76 | $2K | |
| 36591 | <1% | 158 | $2K | |
| 75574 | <1% | 13 | $2K | |
| 96416 | <1% | 19 | $2K | |
| 72197 | <1% | 12 | $2K | |
| 87077 | <1% | 3,611 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,471 | $2K |
| 96368 | <1% | 2,123 | $2K | |
| 95886 | <1% | 40 | $2K | |
| 88300 | <1% | 646 | $2K | |
| 99480 | Subsequent intensive care, per day, low birth weight infant | <1% | 41 | $2K |
| 87186 | <1% | 4,784 | $2K | |
| 99349 | <1% | 35 | $2K | |
| C1758 | Catheter, ureteral | <1% | 1,648 | $2K |
| 87070 | <1% | 2,185 | $2K | |
| 87486 | <1% | 151 | $2K | |
| 87581 | <1% | 209 | $2K | |
| 96040 | <1% | 79 | $2K | |
| 82746 | <1% | 1,074 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 19 | $2K |
| 93246 | <1% | 445 | $2K | |
| 72128 | <1% | 103 | $2K | |
| 76881 | <1% | 28 | $2K | |
| 77300 | <1% | 46 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 16,603 | $2K |
| 82803 | <1% | 4,655 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,495 | $2K |
| 87420 | <1% | 67 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 18 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,946 | $2K |
| 85652 | <1% | 3,542 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 18,015 | $2K |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 192 | $1K |
| 93312 | <1% | 27 | $1K | |
| 92610 | <1% | 57 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,637 | $1K |
| 87210 | <1% | 2,660 | $1K | |
| 86780 | <1% | 296 | $1K | |
| 73560 | <1% | 67 | $1K | |
| 85014 | <1% | 2,276 | $1K | |
| 73660 | <1% | 92 | $1K | |
| 82375 | <1% | 4,689 | $1K | |
| 85018 | <1% | 2,643 | $1K | |
| 85730 | <1% | 3,327 | $1K | |
| 84100 | <1% | 4,137 | $1K | |
| 99254 | <1% | 12 | $1K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 310 | $1K |
| 87808 | <1% | 2,567 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,724 | $1K |
| 82247 | <1% | 1,139 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 11,306 | $1K |
| J3490 | Unclassified drugs | <1% | 729 | $1K |
| 99443 | <1% | 122 | $1K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 24 | $967.34 |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 26 | $952.64 |
| 99253 | <1% | 13 | $932.47 | |
| 82550 | <1% | 2,145 | $910.52 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,233 | $887.61 |
| 88312 | <1% | 69 | $873.02 | |
| Q3014 | Telehealth originating site facility fee | <1% | 105 | $866.63 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 567 | $860.81 |
| 80164 | <1% | 125 | $847.53 | |
| 87147 | <1% | 1,981 | $841.85 | |
| 80306 | <1% | 709 | $838.79 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 525 | $826.65 |
| 82570 | <1% | 1,442 | $810.18 | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 126 | $807.55 |
| 99152 | <1% | 1,776 | $792.64 | |
| 87150 | <1% | 155 | $782.00 | |
| 74022 | <1% | 186 | $768.60 | |
| 84156 | <1% | 1,478 | $733.85 | |
| 87340 | <1% | 689 | $705.46 | |
| 98968 | <1% | 17 | $704.43 | |
| 0124A | <1% | 41 | $680.00 | |
| 99221 | <1% | 15 | $675.12 | |
| 82075 | <1% | 965 | $673.13 | |
| 82378 | <1% | 109 | $671.29 | |
| 93247 | <1% | 16 | $646.98 | |
| 87205 | <1% | 3,056 | $621.06 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,712 | $614.27 |
| 82810 | <1% | 3,803 | $601.97 | |
| 99495 | <1% | 43 | $568.20 | |
| 72170 | <1% | 204 | $563.99 | |
| 87075 | <1% | 1,633 | $559.60 | |
| 93296 | <1% | 216 | $530.26 | |
| 76604 | <1% | 14 | $530.15 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,019 | $526.67 |
| 87641 | <1% | 40 | $520.18 | |
| D1206 | Topical application of fluoride varnish | <1% | 25 | $511.04 |
| 88189 | <1% | 22 | $496.02 | |
| 85007 | <1% | 791 | $490.58 | |
| 80069 | <1% | 278 | $489.12 | |
| 99499 | <1% | 14 | $486.64 | |
| 76000 | <1% | 119 | $460.84 | |
| 84550 | <1% | 1,504 | $460.81 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 996 | $426.20 |
| 90680 | <1% | 36 | $397.35 | |
| 99429 | <1% | 12 | $387.94 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 5,931 | $381.83 |
| 82040 | <1% | 501 | $367.23 | |
| 87088 | <1% | 844 | $366.50 | |
| 99441 | <1% | 12 | $356.65 | |
| 72114 | <1% | 14 | $356.44 | |
| 73060 | <1% | 74 | $345.97 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,357 | $337.89 |
| 92611 | <1% | 56 | $307.42 | |
| 85045 | <1% | 266 | $302.58 | |
| 82010 | <1% | 1,294 | $300.67 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,766 | $273.50 |
| 69209 | <1% | 32 | $254.12 | |
| 90697 | <1% | 12 | $249.25 | |
| 83615 | <1% | 220 | $246.37 | |
| 90723 | <1% | 12 | $229.10 | |
| 71101 | <1% | 12 | $222.69 | |
| 88112 | <1% | 99 | $219.21 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,117 | $210.81 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,910 | $188.57 |
| 84165 | <1% | 64 | $188.02 | |
| 84132 | <1% | 1,063 | $170.69 | |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 131 | $168.90 |
| 71100 | <1% | 27 | $168.43 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,463 | $163.78 |
| 90633 | <1% | 14 | $155.33 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 459 | $141.04 |
| 82140 | <1% | 425 | $137.83 | |
| 90647 | <1% | 12 | $133.40 | |
| 73552 | <1% | 49 | $130.28 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 276 | $119.50 |
| 86803 | <1% | 183 | $115.65 | |
| 74019 | <1% | 12 | $111.58 | |
| 87899 | <1% | 164 | $108.04 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 54 | $107.73 |
| 0296T | <1% | 48 | $95.27 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 557 | $92.43 |
| 86300 | <1% | 30 | $80.04 | |
| 84450 | <1% | 472 | $79.97 | |
| A9270 | Non-covered item or service | <1% | 14,817 | $79.91 |
| 80177 | <1% | 25 | $79.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,661 | $77.42 |
| 85049 | <1% | 110 | $77.27 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,347 | $73.26 |
| 90674 | <1% | 27 | $73.08 | |
| 94644 | <1% | 27 | $71.61 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 417 | $68.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,740 | $64.60 |
| 93280 | <1% | 212 | $59.86 | |
| 51798 | <1% | 87 | $59.20 | |
| 70360 | <1% | 12 | $57.82 | |
| 86705 | <1% | 52 | $57.52 | |
| 84295 | <1% | 478 | $55.35 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,941 | $55.20 |
| 77062 | <1% | 188 | $51.30 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 165 | $49.89 |
| 0297T | <1% | 48 | $47.64 | |
| L3807 | Wrist hand finger orthosis, without joint(s), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 25 | $47.00 |
| 86308 | <1% | 134 | $41.01 | |
| 86317 | <1% | 12 | $37.92 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,201 | $36.85 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 137 | $36.11 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,988 | $34.80 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 273 | $27.82 |
| 82947 | <1% | 424 | $27.65 | |
| L3260 | Surgical boot/shoe, each | <1% | 79 | $23.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 895 | $22.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,105 | $18.23 |
| A4565 | Slings | <1% | 677 | $16.00 |
| 86765 | <1% | 15 | $13.38 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 499 | $12.86 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 39 | $12.68 |
| 99406 | <1% | 51 | $11.03 | |
| 86703 | <1% | 32 | $10.71 | |
| 82435 | <1% | 375 | $10.71 | |
| Q4049 | Finger splint, static | <1% | 129 | $6.00 |
| 86709 | <1% | 13 | $4.04 | |
| 89051 | 0% | 62 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 143 | $0.00 |
| 96417 | 0% | 503 | $0.00 | |
| 0502F | 0% | 168 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 229 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 988 | $0.00 |
| 77061 | 0% | 146 | $0.00 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 57 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 625 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 141 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 1,806 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 13 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 808 | $0.00 |
| J1460 | Injection, gamma globulin, intramuscular, 1 cc | 0% | 16 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 721 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 68 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 191 | $0.00 |
| 51702 | 0% | 59 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 81 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 43 | $0.00 |
| 85347 | 0% | 74 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 90 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 57 | $0.00 |
| 64636 | 0% | 28 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 55 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 119 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 28 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 38 | $0.00 |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | 0% | 27 | $0.00 |
| 88360 | 0% | 59 | $0.00 | |
| J2359 | Injection, olanzapine, 0.5 mg | 0% | 153 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| Q4101 | Apligraf, per square centimeter (add-on, list separately in addition to primary procedure) | 0% | 62 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 25 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 14 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 13 | $0.00 |
| 88313 | 0% | 13 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 593 | $0.00 |
| C1769 | Guide wire | 0% | 2,067 | $0.00 |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 244 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 509 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 374 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 468 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 315 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 117 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 628 | $0.00 |
| 96411 | 0% | 61 | $0.00 | |
| 90474 | 0% | 12 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 467 | $0.00 |
| G0269 | Placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug) | 0% | 18 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 379 | $0.00 |
| 64494 | 0% | 159 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 152 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 77 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 58 | $0.00 |
| 82945 | 0% | 12 | $0.00 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | 0% | 46 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 186 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 12 | $0.00 |
| 0346T | 0% | 30 | $0.00 | |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | 0% | 12 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 214 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 39 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 20 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 24 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 44 | $0.00 |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 0% | 24 | $0.00 |
| 85032 | 0% | 16 | $0.00 | |
| 84157 | 0% | 12 | $0.00 | |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSEIRER, JEFFREY (SYS VP FIN INTEGRITY/CONTROLLER)
| Provider | Location | Paid |
|---|---|---|
| Peacehealth | Longview, WA | $48.29M |
| Peacehealth | Bellingham, WA | $47.27M |
| Peacehealth | Springfield, OR | $30.72M |
| Peacehealth | Eugene, OR | $13.35M |
| Peacehealth | Vancouver, WA | $2.56M |
| Peacehealth | Eugene, OR | $1.84M |
| Peacehealth | Friday Harbor, WA | $1.06M |
| Peacehealth | Vancouver, WA | $1.00M |
| Peacehealth | Vancouver, WA | $814K |
| Peacehealth | Springfield, OR | $395K |
| Peacehealth | Bellingham, WA | $77K |
| Peacehealth | Kelso, WA | $13K |
| Peacehealth | Ketchikan, AK | $9K |
| Peacehealth | Eugene, OR | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.